Condition: Solid Tumors · Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
This study is an open, multicenter Phase I/II clinical trial, divided into two stages: dose exploration (including dose escalation and dose extension) and efficacy extension.
This description comes directly from the study's public registry record.
Yunpeng Jin · +86-021-61053363 · yunpeng.jin.yj1@hengrui.com
Yuting Wang · +86-021-61053363 · yuting.wang@hengrui.com
Always discuss trial participation with your own doctor first.
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07231211